Paul M. Barr, MD | Authors

Paul M. Barr, MD, Discussed 7-Year Follow-Up Data for Ibrutinib as Frontline Treatment of CLL

June 04, 2021

CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about data from RESONATE-2 showing sustained progression-free and overall survival in patients with chronic lymphocytic leukemia being treated with ibrutinib in the frontline setting.

Diffuse Large B-Cell Lymphoma in the Very Elderly: The Case for Refining Our Clinical Trials

February 16, 2013

Further prospective clinical trials in very elderly patients with DLBCL are clearly needed. Complementing the growing need for such trials, an evolving clinical trial infrastructure, geriatric oncology support, and novel therapeutics are making such studies feasible in the current era.